Thomas B K Watkins
Overview
Explore the profile of Thomas B K Watkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
7981
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al Bakir M, Reading J, Gamble S, Rosenthal R, Uddin I, Rowan A, et al.
Nature
. 2025 Feb;
PMID: 39972134
Neoantigen vaccines are under investigation for various cancers, including epidermal growth factor receptor (EGFR)-driven lung cancers. We tracked the phylogenetic history of an EGFR mutant lung cancer treated with erlotinib,...
2.
Bentham R, Jones T, Black J, Martinez-Ruiz C, Dietzen M, Litovchenko M, et al.
Nat Genet
. 2025 Feb;
57(3):694-705.
PMID: 39966644
Recognition and elimination of pathogens and cancer cells depend on the adaptive immune system. Thus, accurate quantification of immune subsets is vital for precision medicine. We present immune lymphocyte estimation...
3.
Bailey C, Pich O, Thol K, Watkins T, Luebeck J, Rowan A, et al.
Nature
. 2024 Nov;
635(8037):193-200.
PMID: 39506150
Extrachromosomal DNA (ecDNA) is a major contributor to treatment resistance and poor outcome for patients with cancer. Here we examine the diversity of ecDNA elements across cancer, revealing the associated...
4.
Frankell A, Dietzen M, Al Bakir M, Lim E, Karasaki T, Ward S, et al.
Nature
. 2024 Jul;
631(8022):E15.
PMID: 38965439
No abstract available.
5.
Hobor S, Al Bakir M, Hiley C, Skrzypski M, Frankell A, Bakker B, et al.
Nat Commun
. 2024 Jun;
15(1):4871.
PMID: 38871738
The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here,...
6.
Watkins T, Colliver E, Huska M, Kaufmann T, Lim E, Duncan C, et al.
PLoS Comput Biol
. 2023 Oct;
19(10):e1011379.
PMID: 37871126
Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease...
7.
Abbosh C, Frankell A, Harrison T, Kisistok J, Garnett A, Johnson L, et al.
Nature
. 2023 Apr;
616(7957):553-562.
PMID: 37055640
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy. The study of large patient cohorts incorporating longitudinal plasma sampling and...
8.
Frankell A, Dietzen M, Al Bakir M, Lim E, Karasaki T, Ward S, et al.
Nature
. 2023 Apr;
616(7957):525-533.
PMID: 37046096
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell...
9.
Al Bakir M, Huebner A, Martinez-Ruiz C, Grigoriadis K, Watkins T, Pich O, et al.
Nature
. 2023 Apr;
616(7957):534-542.
PMID: 37046095
Metastatic disease is responsible for the majority of cancer-related deaths. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in...
10.
Ng K, Boumelha J, Enfield K, Almagro J, Cha H, Pich O, et al.
Nature
. 2023 Apr;
616(7957):563-573.
PMID: 37046094
B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid structures (TLS). Although TLS have been found to correlate...